Submit Manuscript  

Article Details


New Compounds Targeting the Androgen Receptor for Treatment of Advanced Prostate Cancer

[ Vol. 17 , Issue. 3 ]

Author(s):

Rita Assi, Sally Temraz, Ali Shamseddine and Deborah Mukherji   Pages 290 - 302 ( 13 )

Abstract:


The androgen receptor (AR) signalling pathway remains a key driver of prostate cancer progression despite castrate levels of testosterone in advanced disease. The androgen biosynthesis inhibitor abiraterone and the anti-androgen enzalutamide have been shown to prolong survival in randomized clinical trials both pre-and post-docetaxel chemotherapy and are now in routine clinical use. With the use of these drugs and other novel survival-prolonging therapeutics, patients with advanced prostate cancer are now living longer with better quality of life. This article will review pre-clinical and clinical data for AR-targeting therapeutics for advanced prostate cancer with a focus on mechanisms of resistance and future directions for research.

Keywords:

Prostate cancer, androgen receptor, abiraterone, enzalutamide.

Affiliation:

Department of Internal Medicine, Division of Hematology Oncology American University of Beirut Medical Center Beirut, Lebanon

Graphical Abstract:



Read Full-Text article